
About this episode
In this episode, Dr. Harlan Krumholz introduces the September 16, 2025 issue of JACC, which features studies that challenge conventional clinical thinking, including a detailed ECMO physiology study showing that higher ECMO flow does not uniformly raise pulmonary capillary wedge pressure, suggesting the need for individualized management. A novel analysis of the ISCHEMIA trial revealed distinct angina symptom trajectories, emphasizing that recovery is not binary and supporting a more personalized approach to treatment and monitoring. A landmark target trial emulation found that statins significantly reduce cardiovascular risk in patients with type 1 diabetes—filling a key evidence gap. Additional highlights include a call to redefine early cardiogenic shock, a nuanced review of moderate secondary mitral regurgitation, and an editorial reaffirming JACC's commitment to independent, transparent science in alignment with new "Gold Standard Science" principles.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week

March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week

February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week

February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week